Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

First Line ◽

Highly Active ◽

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial

AIDS ◽

10.1097/qad.0b013e3283428cbe ◽

2011 ◽

Vol 25 (4) ◽

pp. 479-492 ◽

Cited By ~ 21

Author(s):

Andrea L Ciaranello ◽

Shahin Lockman ◽

Kenneth A Freedberg ◽

Michael Hughes ◽

Jennifer Chu ◽

...

Keyword(s):

South Africa ◽

Single Dose ◽

Cost Effectiveness ◽

Antiretroviral Therapy ◽

First Line ◽

Effectiveness Analysis ◽

Single Dose Nevirapine

Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection

HIV Clinical Trials ◽

10.1310/wt81-mem4-5c4l-chpk ◽

2004 ◽

Vol 5 (5) ◽

pp. 294-304 ◽

Cited By ~ 46

Author(s):

Kit N. Simpson ◽

Michelle P. Luo ◽

Elinor Chumney ◽

Eugene Sun ◽

Scott Brun ◽

...

Keyword(s):

Cost Effectiveness ◽

Antiretroviral Therapy ◽

Hiv Infection ◽

Highly Active Antiretroviral Therapy ◽

First Line ◽

Therapy Regimen ◽

Highly Active

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

First Line ◽

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Unresectable Hepatocellular Carcinoma

First Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1607 ◽

2016 ◽

Vol 19 (3) ◽

pp. A153

Author(s):

W Cheng ◽

JW Hay

Keyword(s):

Pancreatic Cancer ◽

Cost Effectiveness ◽

Societal Perspective ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

The Us ◽

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe

PLoS ONE ◽

10.1371/journal.pone.0033672 ◽

2012 ◽

Vol 7 (4) ◽

pp. e33672 ◽

Cited By ~ 19

Author(s):

Antonieta Medina Lara ◽

Jesse Kigozi ◽

Jovita Amurwon ◽

Lazarus Muchabaiwa ◽

Barbara Nyanzi Wakaholi ◽

...

Keyword(s):

Cost Effectiveness ◽

Antiretroviral Therapy ◽

Laboratory Monitoring ◽

Routine Laboratory ◽

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

International Urogynecology Journal ◽

10.1007/s00192-018-3662-y ◽

2018 ◽

Vol 29 (8) ◽

pp. 1221-1221

Author(s):

Abdelmageed Abdelrahman

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Onabotulinumtoxin A ◽